Antibody–drug conjugates for targeted anticancer drug delivery

다국어 초록 (Multilingual Abstract)

Antibody–drug conjugates (ADCs) are tumortargeted therapeutic agents that combine the specificity of monoclonal antibodies (mAbs) with the potent anti-tumor effects of cytotoxic drugs. Over the past few years, ADCs have become a powerful tool in the field of cancer chemotherapy. Recently, two ADC products, brentuximab vedotin (Adcetris) and trastuzumab emtansine (Kadcyla ), have received FDA approval and there are more than 40 ADC candidates in clinical trials for the treatment of various cancers. Despite the success of some products, considerable interests for the next generation of ADCs have focused on the development of homogeneous conjugates because most of the current ADCs are highly heterogeneous with different drug-to-antibody ratios and drug conjugation sites. Recent studies have demonstrated that the site-specific conjugation of drugs to mAbs could produce homogeneous ADC with better pharmacokinetic properties and improved therapeutic index. A number of approaches, including the use of engineered cysteines, the insertion of unnatural amino acids, and enzymatic ligation, have addressed the challenging issues for the synthesis of homogeneous ADC. This review discusses the limitations of current ADC technologies and describes recent site-specific conjugation methods that can be used to prepare homogeneous ADCs for targeted anticancer drug delivery.

참고문헌 (Reference)

1 Barok M., "Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo" 13 : R46-, 2011

2 Harding FA., "The immunogenicity of humanized and fully human antibodies : residual immunogenicity resides in the CDR regions" 2 : 256-265, 2010

3 Senter PD., "The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma" 30 : 631-637, 2012

4 van der Velden VH., "Targeting of the CD33-calicheamicin immunoconjugate Mylotarg(CMA-676)in acute myeloid leukemia : in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells" 97 : 3197-3204, 2001

5 Axup JY., "Synthesis of site-specific antibody-drug conjugates using unnatural amino acids" 109 : 16101-16106, 2012

6 Wang L., "Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry" 14 : 2436-2446, 2005

7 Eunhee G. Kim, "Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics" 한국응용약물학회 23 (23): 493-509, 2015

8 Stimmel JB., "Site-specific conjugation on serine right-arrow cysteine variant monoclonal antibodies" 275 : 30445-30450, 2000

9 Junutula JR., "Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index" 26 : 925-932, 2008

10 Rabuka D., "Site-specific chemical protein conjugation using genetically encoded aldehyde tags" 7 : 1052-1067, 2012

11 Panowski S., "Site-specific antibody drug conjugates for cancer therapy" 6 : 34-45, 2014

12 Jeger S., "Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase" 49 : 9995-9997, 2010

13 Advani A., "Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma : results of a phase I study" 28 : 2085-2093, 2010

14 Kung Sutherland MS., "SGN-CD33A : a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML" 122 : 1455-1463, 2013

15 Riechmann L., "Reshaping human antibodies for therapy" 332 : 323-327, 1988

16 Sun MM., "Reduction–alkylation strategies for the modification of specific monoclonal antibody disulfides" 16 : 1282-1290, 2005

17 Chudasama V., "Recent advances in the construction of antibody-drug conjugates" 8 : 114-119, 2016

18 Junutula JR., "Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs" 332 : 41-52, 2008

19 Yokoyama K., "Properties and applications of microbial transglutaminase" 64 : 447-454, 2004

20 Reichert JM., "Monoclonal antibody successes in the clinic" 23 : 1073-1078, 2005

21 Hofer T., "Molecularly defined antibody conjugation through a selenocysteine interface" 48 : 12047-12057, 2009

22 Behrens CR., "Methods for site-specific drug conjugation to antibodies" 6 : 46-53, 2014

23 Sukumaran S., "Mechanism-based pharmacokinetic/pharmacodynamic model for THIOMAB™ drug conjugates" 32 : 1884-1893, 2015

24 Strop P., "Location matters : site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates" 20 : 161-167, 2013

25 Feld J., "Linked-in : design and efficacy of antibody drug conjugates in oncology" 4 : 397-412, 2013

26 Takimoto JK., "Improving orthogonal tRNA-synthetase recognition for efficient unnatural amino acid incorporation and application in mammalian cells" 5 : 931-934, 2009

27 Burnett AK., "Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin : results of the MRC AML15 trial" 29 : 369-377, 2011

28 Schroff RW., "Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy" 45 : 879-885, 1985

29 Hamann PR., "Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia" 13 : 47-58, 2002

30 Kubota T., "Engineered therapeutic antibodies with improved effector functions" 100 : 1566-1572, 2009

31 McDonagh CF., "Engineered antibody–drug conjugates with defined sites and stoichiometries of drug attachment" 19 : 299-307, 2006

32 Hamblett KJ., "Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate" 10 : 7063-7070, 2004

33 Doronina SO., "Development of potent monoclonal antibody auristatin conjugates for cancer therapy" 21 : 778-784, 2003

34 Sochaj AM., "Current methods for the synthesis of homogeneous antibody–drug conjugates" 33 : 775-784, 2015

35 Alley SC., "Contribution of linker stability to the activities of anticancer immunoconjugates" 19 : 759-765, 2008

36 Shen BQ., "Conjugation site modulates the in vivo stability and therapeutic activity of antibody–drug conjugates" 30 : 184-189, 2012

37 Girish S., "Clinical pharmacology of trastuzumab emtansine(T-DM1) : an antibody–drug conjugate in development for the treatment of HER2-positive cancer" 69 : 1229-1240, 2012

38 Walker S., "Cleavage behavior of calicheamicin gamma 1 and calicheamicin T" 89 : 4608-4612, 1992

39 Pro B., "Brentuximab vedotin(SGN-35)in patients with relapsed or refractory systemic anaplastic large-cell lymphoma : results of a phase II study" 30 : 2190-2196, 2012

40 Katz J., "Brentuximab vedotin(SGN-35)" 17 : 6428-6436, 2011

41 Younes A., "Brentuximab vedotin" 11 : 19-20, 2012

42 Bross PF., "Approval summary gemtuzumab ozogamicin in relapsed acute myeloid leukemia" 7 : 1490-1496, 2001

43 Na DH., "Application of sodium dodecyl sulfate-capillary gel electrophoresis to the characterization of ricin A-chain immunotoxins" 75 : 679-683, 2012

44 Kitson SL., "Antibody–drug conjugates(ADCs)—biotherapeutic bullets" 31 : 30-36, 2013

45 Ricart AD, "Antibody–drug conjugates of calicheamicin derivative : gemtuzumab ozogamicin and inotuzumab ozogamicin" 17 : 6417-6427, 2011

46 Sievers EL., "Antibody–drug conjugates in cancer therapy" 64 : 15-29, 2013

47 Peters C., "Antibody–drug conjugates as novel anti-cancer chemotherapeutics" 35 : e00225-, 2015

48 Ducry L., "Antibody–drug conjugates : linking cytotoxic payloads to monoclonal antibodies" 21 : 5-13, 2009

49 Perez HL., "Antibody–drug conjugates : current status and future directions" 19 : 869-881, 2014

50 DiJoseph JF., "Antibody-targeted chemotherapy with CMC-544 : a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies" 103 : 1807-1814, 2004

51 Scott AM., "Antibody therapy of cancer" 12 : 278-287, 2012

52 McCombs JR., "Antibody drug conjugates : design and selection of linker, payload and conjugation chemistry" 17 : 339-351, 2015

53 Li X., "Antibody conjugation via one and two C-terminal selenocysteines" 65 : 133-138, 2014

54 Teicher BA., "Antibody conjugate therapeutics : challenges and potential" 17 : 6389-6397, 2011

55 Drake PM., "Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes" 25 : 1331-1341, 2014